Display options
Cite
Prylutska SV, Skivka LM, Didenko GV, et al. Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy. Nanoscale Res Lett. 2015;10(1):499doi: 10.1186/s11671-015-1206-7.
Prylutska, S. V., Skivka, L. M., Didenko, G. V., Prylutskyy, Y. I., Evstigneev, M. P., Potebnya, G. P., Panchuk, R. R., Stoika, R. S., Ritter, U., & Scharff, P. (2015). Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy. Nanoscale research letters, 10(1), 499. https://doi.org/10.1186/s11671-015-1206-7
Prylutska, Svitlana V, et al. "Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy." Nanoscale research letters vol. 10,1 (2015): 499. doi: https://doi.org/10.1186/s11671-015-1206-7
Prylutska SV, Skivka LM, Didenko GV, Prylutskyy YI, Evstigneev MP, Potebnya GP, Panchuk RR, Stoika RS, Ritter U, Scharff P. Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy. Nanoscale Res Lett. 2015 Dec;10(1):499. doi: 10.1186/s11671-015-1206-7. Epub 2015 Dec 29. PMID: 26714861; PMCID: PMC4695471.
Copy Download .nbib Format: NLM
Share it on

Nanoscale Res Lett. 2015 Dec;10(1):499. doi: 10.1186/s11671-015-1206-7. Epub 2015 Dec 29.

Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy.

Nanoscale research letters

Svitlana V Prylutska, Larysa M Skivka, Gennadiy V Didenko, Yuriy I Prylutskyy, Maxim P Evstigneev, Grygoriy P Potebnya, Rostyslav R Panchuk, Rostyslav S Stoika, Uwe Ritter, Peter Scharff

Affiliations

  1. Taras Shevchenko National University of Kyiv, 64 Volodymyrska Str., 01601, Kyiv, Ukraine. [email protected].
  2. Taras Shevchenko National University of Kyiv, 64 Volodymyrska Str., 01601, Kyiv, Ukraine. [email protected].
  3. R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NASU, Vasylkivska Str. 45, 03022, Kyiv, Ukraine. [email protected].
  4. Taras Shevchenko National University of Kyiv, 64 Volodymyrska Str., 01601, Kyiv, Ukraine. [email protected].
  5. Belgorod State University, Pobedy Str.85, 308015, Belgorod, Russia. [email protected].
  6. R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of NASU, Vasylkivska Str. 45, 03022, Kyiv, Ukraine. [email protected].
  7. Institute of Cell Biology, NAS of Ukraine, 14-16 Drahomanov Str., 79005, Lviv, Ukraine. [email protected].
  8. Institute of Cell Biology, NAS of Ukraine, 14-16 Drahomanov Str., 79005, Lviv, Ukraine. [email protected].
  9. Technical University of Ilmenau, Institute of Chemistry and Biotechnology, 25 Weimarer Str., 98693, Ilmenau, Germany. [email protected].
  10. Technical University of Ilmenau, Institute of Chemistry and Biotechnology, 25 Weimarer Str., 98693, Ilmenau, Germany. [email protected].

PMID: 26714861 PMCID: PMC4695471 DOI: 10.1186/s11671-015-1206-7

Abstract

The main aim of this work was to evaluate the effect of doxorubicin in complex with C60 fullerene (C60 + Dox) on the growth and metastasis of Lewis lung carcinoma in mice and to perform a primary screening of the potential mechanisms of C60 + Dox complex action. We found that volume of tumor from mice treated with the C60 + Dox complex was 1.4 times less than that in control untreated animals. The number of metastatic foci in lungs of animals treated with C60 + Dox complex was two times less than that in control untreated animals. Western blot analysis of tumor lysates revealed a significant decrease in the level of heat-shock protein 70 in animals treated with C60 + Dox complex. Moreover, the treatment of tumor-bearing mice was accompanied by the increase of cytotoxic activity of immune cells. Thus, the potential mechanisms of antitumor effect of C60 + Dox complex include both its direct action on tumor cells by inducing cell death and increasing of stress sensitivity and an immunomodulating effect. The obtained results provide a scientific basis for further application of C60 + Dox nanocomplexes as treatment agents in cancer chemotherapy.

Keywords: Antimetastatic effect; Antitumor effect; C60 fullerene; Doxorubicin; Immune response

References

  1. JAMA. 2006 Sep 27;296(12):1518-20 - PubMed
  2. Langmuir. 2014 Apr 15;30(14):3967-70 - PubMed
  3. Cancer Lett. 2013 May 28;332(2):275-85 - PubMed
  4. Chemphyschem. 2013 Feb 25;14(3):568-78 - PubMed
  5. Curr Drug Metab. 2012 Oct;13(8):1035-45 - PubMed
  6. Postepy Hig Med Dosw (Online). 2006;60:78-100 - PubMed
  7. Exp Oncol. 2011 Sep;33(3):162-4 - PubMed
  8. Annu Rev Immunol. 2006;24:257-86 - PubMed
  9. Nano Lett. 2005 Dec;5(12):2578-85 - PubMed
  10. Scientifica (Cairo). 2013;2013:217513 - PubMed
  11. Curr Med Chem. 2011;18(14):2045-59 - PubMed
  12. Phys Chem Chem Phys. 2013 Jun 21;15(23):9351-60 - PubMed
  13. Cell Cycle. 2006 Aug;5(16):1779-87 - PubMed
  14. Drugs R D. 2014 Dec;14(4):333-40 - PubMed
  15. Toxicol Sci. 2010 Apr;114(2):162-82 - PubMed
  16. Nanoscale. 2014 Apr 7;6(7):3488-95 - PubMed
  17. Theranostics. 2012;2(3):238-50 - PubMed
  18. Phys Chem Chem Phys. 2014 Nov 14;16(42):23164-72 - PubMed
  19. Br J Cancer. 2003 Jul 21;89(2):357-62 - PubMed
  20. Circulation. 2013 Jul 9;128(2):152-61 - PubMed
  21. J Biomed Nanotechnol. 2012 Jun;8(3):522-7 - PubMed
  22. Autophagy. 2009 Nov;5(8):1107-17 - PubMed
  23. Small. 2008 Aug;4(8):1168-75 - PubMed
  24. Pharmacol Rep. 2009 Mar-Apr;61(2):335-42 - PubMed
  25. Biomaterials. 2008 Sep;29(26):3561-73 - PubMed

Publication Types